Literature DB >> 16628189

Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors.

G Jego1, R Bataille, A Geffroy-Luseau, G Descamps, C Pellat-Deceunynck.   

Abstract

Multiple myeloma (MM) patients are strongly vulnerable to infections, which remain a major cause of death. During infection, human immune cells sense the presence of invading pathogens through the Toll-like receptor family (TLR), which recognizes pathogen-associated molecular patterns (PAMP). We hypothesized that MM cells also could sense the presence of microorganisms, thus promoting myeloma disease progression. Here, we report that human myeloma cell lines (HMCL) and primary myeloma cells express a broad range of TLR, and are sensitive to the corresponding PAMP. Toll-like receptor 1, 7 and 9 are most frequently expressed by HMCL. The expression pattern of TLR does not correlate with the one of B cells, as TLR2 and 10 are lost while TLR3, 4 and 8 are acquired by some HMCL. Culture with TLR7- and TLR9-ligands saves HMCL from serum-deprivation or dexamethasone-induced apoptosis. Similarly, both ligands increase myeloma cell growth. These effects are mediated by an autocrine secretion of interleukin-6 (IL-6) since the neutralization of IL-6 blocks the growth and survival of HMCL. Thus, TLR expression and function are not restricted to the cells of the immune system and could be of advantage for cancer cells. In MM, recurrent infections could promote tumor growth and favor escape from standard therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16628189     DOI: 10.1038/sj.leu.2404226

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  52 in total

Review 1.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

Review 2.  Toll-like receptors and cancer.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Nat Rev Cancer       Date:  2008-12-04       Impact factor: 60.716

Review 3.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

Review 4.  Toll-like receptors--sentries in the B-cell response.

Authors:  Isabelle Bekeredjian-Ding; Gaetan Jego
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

Review 5.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

6.  Maltose-binding protein isolated from Escherichia coli induces Toll-like receptor 2-mediated viability in U937 cells.

Authors:  Zhao Xiaoxia; Ni Weihua; Zhang Qingyong; Wang Fengli; Li Yingying; Sun Xiaxia; Liu Zhonghui; Tai Guixiang
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

Review 7.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Toll-like receptor signaling in cell proliferation and survival.

Authors:  Xinyan Li; Song Jiang; Richard I Tapping
Journal:  Cytokine       Date:  2009-09-22       Impact factor: 3.861

9.  p52-Independent nuclear translocation of RelB promotes LPS-induced attachment.

Authors:  T Saito; C Y Sasaki; L J Rezanka; P Ghosh; D L Longo
Journal:  Biochem Biophys Res Commun       Date:  2009-11-10       Impact factor: 3.575

10.  High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer.

Authors:  E L Wang; Z R Qian; M Nakasono; T Tanahashi; K Yoshimoto; Y Bando; E Kudo; M Shimada; T Sano
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.